secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001437749-24-016818
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics Q1 net loss $4.3M; $9.4M raised; pipeline progress on AJ201, BAER-101, IV tramadol
--------------------------------------------------------------------------------

- Net loss $4.3M ($15.40/share) vs $7.5M ($101.57) in Q1 2023; R&D $2.4M, G&A $1.3M.
- Cash $3.2M at Mar 31, up from $1.8M; additional $4.4M gross proceeds from May 2024 warrant exercise.
- AJ201 topline data for Kennedy's Disease expected mid-2024; received FDA agreement on IV tramadol Phase 3 protocol.
- Total $9.4M raised from warrant exercises in Jan and May 2024; 1-for-75 reverse split in April to regain Nasdaq compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000143774924016818/0001437749-24-016818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000143774924016818/atxi20240113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer